BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:12 PM
 | 
Oct 04, 2007
 |  BC Extra  |  Clinical News

Merck's CETP inhibitor meets primary endpoint

MRK said anacetrapib ( MK-0859) met the primary endpoint of a significant reduction in LDL-C vs. placebo in a Phase IIb trial to treat dyslipidemia. In the double-blind study in 589 patients, doses of 10, 40, 150 and 300...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >